Vinge advises Santander Consumer Finance in connection with its acquisition of all shares in Athlon Sweden AB, which is part of Mercedes-Benz Mobility.
Vinge advises EQT Healthcare Growth, a new dedicated healthcare buy-out strategy introduced by EQT, in connection with its first investment – the acquisition of the biotech company, Mabtech, from IK Small Cap II Fund and several minority sellers.
Vinge has advised Byggfakta Group Nordic HoldCo AB (publ) in connection with a public takeover offer provided by Stirling Square, TA Associates and Macquarie Capital, through Giant BidCo, to the shareholders of Byggfakta. The offer price is SEK 46 per share and values Byggfakta to approximately SEK 10.1 billion.
Vinge advises Fastighets Aktiebolaget Trianon (publ) in connection with its partial tender offer for outstanding subordinated perpetual floating rate callable sustainable capital securities.
In total, sustainable capital securities with an aggregate nominal amount of SEK 370 million were repurchased. Payment for repurchased sustainable capital securities was made by way of set-off against new newly issued series B shares of the company.
Vinge has advised Svea Bank AB (the “Company”) in connection with its issuance of SEK 300 million additional tier 1 capital bonds (AT1) with a floating rate interest of 3-month STIBOR + 7.50%.
Vinges advises the EQT X fund (or “EQT Private Equity”) in connection with its investment in the Nordic software companies HVD Group (Hantverksdata) and Next (Next One Technology). Both companies serve the tradespeople and construction industry, with HVD Group focused on installation and service professions – such as electricians, plumbers, heating and ventilation firms – while Next is focused on contractors. HVD Group’s platform complements that of Next, and the investment thus paves the way for a further strengthened product offering, which builds on both companies’ strong customer satisfaction scores.
Vinge has advised Region Uppsala in connection with its issuance of a so-called health impact bond in the amount of SEK 80 million and with a tenor of five years. The health impact bond is the second of its kind in the world and comes after Region Stockholm’s bond which was linked to preventive measures against type 2 diabetes. Skandia was the sole investor and SEB acted as financial advisor and issuing agent.
Vinge advises Altor Funds (“Altor”), the founders and the other sellers in connection with Bain Capital Private Equity (“Bain Capital”), a leading global private investment firm, acquiring a controlling stake in Eleda from Altor, which will reinvest a minority share. Eleda’s founders, Johan Halvardsson and Peter Condrup, and senior executives in Eleda will also reinvest a substantial share. Through the transaction, Altor, Eleda and Bain Capital establish a partnership for future expansion.
Due Compliance is a software company which enables organisations to comply with the requirements in relation to Money Laundering and Terrorist Financing (Prevention) Act by providing digital tools for AML, KYC and Risk Assessments.
Vinge has advised Carnegie Investment Bank AB in connection with the acquisition of the business sectors Erik Penser Wealth Management and Erik Penser Corporate Finance as well as the analytical services Penser Access and Penser Future from Erik Penser Bank AB. The consideration for the completed purchase consists of shares in Carnegie and the acquisition is subject to customary conditions from public authorities.
Vinge has advised atNorth AB, a leading Nordic data center services company that offers responsible, power-efficient, cost-optimized data center hosting facilities and high-performance computing services, in connection with its acquisition of Gompute and its Spanish subsidiary.
Vinge is advising Studentbostäder i Norden AB (publ), a real estate company whose shares are listed on Nasdaq First North Premier Growth Market, in connection with a fully guaranteed rights issue amounting to a total of SEK 331 million before deduction of transaction costs and the amendments to the terms and conditions of the company’s outstanding green 2021/2024 notes with ISIN SE0015960802 (the “Notes”) by way of a written procedure.
Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), an innovative and integrated pharmaceutical company focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment, listed on Nasdaq Stockholm, in connection with a combined financing comprising a SEK 172 million equity private placement and a SEK 290 million debt financing.
Vinge has advised Stendörren Fastigheter AB in connection with its issuance of senior unsecured green notes in an amount of SEK 500 million (within a framework of SEK 600 million) and its parallel tender offer in respect of its previously issued notes due 2024.
